20th CMHC On Demand

REPLACE BELOW

There is a registration fee for this activity (if you were a live attendee please refer to the below note). Registration can be found here. Once registration is complete, you will receive a confirmation email with an access code and link back to this course.

If you attended the 2024 annual meeting, please reach out to [email protected] and we will provide you with complimentary access code to this activity.

Target Audience

The educational design of this activity addresses the needs of US-based healthcare professionals, including cardiologists, endocrinologists, lipidologists, primary care clinicians (PCPs), registered nurses, advanced practice registered nurses, dieticians, pharmacists, and other allied health professionals involved in the management and treatment of cardiometabolic patients.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Describe the connections between cardiometabolic risk factors and their collective influence on the progression of cardiometabolic diseases, including diabetes, dyslipidemia, hypertension, obesity, kidney disease, and cardiovascular disease
  • Analyze recent evidence and guidelines to enhance the prevention, screening, and management of patients with cardiometabolic risk or established cardiometabolic disease
  • Identify effective strategies for early detection and prevention of cardiometabolic disease, including comprehensive risk factor assessment and lifestyle interventions
  • Design personalized treatment plans for patients with cardiometabolic disease by integrating current and emerging pharmacotherapies, considering safety, efficacy, comorbidities, and patient preferences to improve outcomes
  • Summarize the latest advancements in cardiometabolic therapies to remain informed on the evolving landscape of treatment options
Course summary
Available credit: 
  • 14.00 ACPE Pharmacy
  • 14.00 AMA PRA Category 1 Credit™
  • 14.00 ANCC
  • 14.00 CDE
  • 14.00 Participation
Course opens: 
02/18/2026
Course expires: 
12/31/2026
Rating: 
0

Keynote and FDA Update

KEYNOTE
Celebrating 20 Years of CMHC: From Prevention to Treatment to Cure
Presenters: Christie M. Ballantyne, MD; Deepak L. Bhatt, MD; Robert H. Eckel, MD; Keith C. Ferdinand, MD; Anne L. Peters, MD

FDA Update and Late Breaking Trials
Moderator: Christie M. Ballantyne, MD
Presenters: Deepak L. Bhatt, MD; Robert H. Eckel, MD; Keith C. Ferdinand, MD; Anne L. Peters, MD

Session I: CardioRenal

Advancing Care in HFpEF
Biykem Bozkurt, MD

Avoiding Progression of CKD: Role of Aldosterone and Other Components of RAAS
Matthew R. Weir, MD

Challenging Cardiorenal Cases with Expert Panel Discussion and Audience Q&A
Moderator: Keith C. Ferdinand, MD
Case Presenters: Ana Maria Stanton, MD; Ozan Unlu, MD
Panelists: Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACP; Naomi D.L. Fisher, MD; Chiadi Ndumele, MD; Matthew R. Weir, MD

Session II: Obesity

Opening Remarks
Robert H. Eckel, MD

The Importance of Healthy Lifestyle Behaviors in the Prevention of Cardiovascular Disease
Leonard A. Kaminsky, Ph.D., FACSM, FAHA, MAACVPR

Lancet Commission on Obesity
Robert H. Eckel, MD

Updates in Obesity Pharmacotherapy
Donna H. Ryan, MD

GLP-1 RAs: Do They Benefit Patients with Alzheimer’s Disease, Addictive and Psychiatric Disorders?
Ziyad Al-Aly, MD

Challenging Obesity & Lifestyle Management Cases with Expert Panel Discussion and Audience Q&A
Moderator: Robert H. Eckel, MD
Case Presenters: Layla Abushamat, MD; Rahul Aggarwal, MD
Panelists: Ziyad Al-Aly, MD; Leonard A. Kaminsky, Ph.D., FACSM, FAHA, MAACVPR; Donna H. Ryan, MD

Session III: Diabetes

Opening Remarks
Anne L. Peters, MD

Bridging the Gap: Enhancing Understanding and Treatment of Diabetic Peripheral Neuropathy
A. Gordon Smith, MD, FAAN

Rethinking Diabetes: Understanding the Heterogeneity of Diabetes Typing
Anne L. Peters, MD

Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes
Davida F. Kruger, MSN, APN-BC,BC-ADM

Challenging Diabetes Management Cases with Expert Panel Discussion and Audience Q&A
Moderator: Anne L. Peters, MD
Case Presenters: Davida F. Kruger, MSN, APN-BC,BC-ADM; Eden M. Miller, DO
Panelists: Davida F. Kruger, MSN, APN-BC,BC-ADM; Robert H. Eckel, MD; A. Gordon Smith, MD, FAAN; Eden M. Miller, DO

Session IV: Dyslipidemia/Atherosclerosis/Thrombosis

Opening Remarks
Christie M. Ballantyne, MD

Current and Emerging Therapeutics in Hyperlipidemia
Supported by an educational grant from Esperion Therapeutics, Inc.
Patrick Moriarty, MD; Pamela B. Morris, MD; Pam R. Taub, MD

Emerging Therapies in Dyslipidemia: Spotlight on CETP Inhibitors
Supported by an educational grant from New Amsterdam.
Erin D. Michos, MD; Christie M. Ballantyne, MD

FCS, MCS, Persistent Chylomicronemia, sHTG: What do we do now?
Supported by an educational grant from Arrowhead Pharmaceuticals.
Erin D. Michos, MD; Christie M. Ballantyne, MD

Genetic Testing, Polygenic Risk Scores and Management of Cardiometabolic Disease
Pradeep Natarajan, MD, MMSc

Targeting Inflammation in CVD: What is the Right Approach?
Paul M. Ridker, MD

Challenging Lipid Management Cases with Expert Panel Discussion and Audience Q&A
Moderator: Christie M. Ballantyne, MD
Panelists: Erin D. Michos, MD; Patrick Moriarty, MD; Pamela B. Morris, MD; Pradeep Natarajan, MD, MMSc; Paul M. Ridker, MD; Pam R. Taub, MD
Case Presenters: Layla Abushamat, MD; Yakubu Bene-Alhasan, MD, MPH

Closing Remarks
Christie M. Ballantyne, MD

ESTIMATED TIME TO COMPLETE ACTIVITY
TBD hours

EDUCATIONAL GRANT SUPPORT

This activity is supported in part by an independent educational grant from Novartis Pharmaceuticals Corporation and Amgen. 

JOINT PROVIDERSHIP STATEMENT

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and Cardiometabolic Health Congress (CMHC).  Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team

PHYSICIAN CONTINUING EDUCATION
Partners designates this enduring activity for a maximum of 14 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CONTINUING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 14 contact hours.

Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.

PHARMACY CONTINUING EDUCATION
Partners designates this continuing education activity for 14 contact hour(s) (1.4 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number - TBD. Type of activity: Application

DIETITIAN CONTINUING EDUCATION
This program offers 14 CPEUs for dietitians.

DISCLOSURES
Information on planner and faculty disclosures can be found PDF icon here

DISCLOSURE OF CONFLICT OF INTEREST
Partners requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

METHOD OF PARTICIPATION & REQUEST FOR CREDIT 
NEED TO UPDATE BELOW

There is a registration fee for this activity (if you were a live attendee please refer to the below note). Registration can be found here. Once registration is complete, you will receive a confirmation email with an access code and link back to this course.

If you attended the 2025 annual meeting, please reach out to [email protected] and we will provide you with complimentary access code to this activity.

During the period December 6, 2024 through December 6, 2025, participants must read the learning objectives and faculty disclosures, study the educational activity and complete the evaluation.  Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at [email protected].

For additional information about the accreditation of this activity, please visit https://partnersed.com

For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.

Available Credit

  • 14.00 ACPE Pharmacy
  • 14.00 AMA PRA Category 1 Credit™
  • 14.00 ANCC
  • 14.00 CDE
  • 14.00 Participation
Please login or register to take this course.

Please note the recordings will be accessible on December 6, 2024. We will notify you if this date changes.

There is a registration fee for this activity (if you were a live attendee please refer to the below note). Registration can be found here. Once registration is complete, you will receive a confirmation email with an access code and link back to this course.

If you attended the 2024 annual meeting, please reach out to [email protected] and we will provide you with complimentary access code to this activity.

During the period December 6, 2024 through December 6, 2025, participants must read the learning objectives and faculty disclosures, study the educational activity and complete the evaluation.  Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at [email protected].

For additional information about the accreditation of this activity, please visit https://partnersed.com

For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.

Required Hardware/software

A computer with an internet connection

Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser

Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.